News

In a retrospective study using the data of 20,741 patients, investigators discover the primary cause of emergency department visits for geriatric patients is head trauma.

The inaugural episode of the DocTalk Podcast features a conversation about transcatheter aortic valve replacement with two cardiologists from Brigham and Women's Hospital.

Investigators submit recommendations for physicians for Parkinson disease reflecting recent advancements, including a new section on palliative care.

How a pattern of poor sleep could begin a cycle of worsened respiratory and cardiovascular health.

A study from investigators at Beth Israel Deaconess Medical Center found that more intense hypertensive treatments did not result in added episodes of orthostatic hypotension.

Dr. Rizzo provides a look into the current methods of COPD screening, and how patient treatment potential is changed.

A study from the AHA's Hypertension Scientific Sessions revealed first- and second-year medical students have a 2.4 higher risk of stage 2 hypertension compared to the general public.

The approval for interstitial lung disease associated with systemic sclerosis or scleroderma makes nintedanib the first therapy for the rare condition.

Investigators find that sofosbuvir is less effective on some HCV infections because of certain amino acid substitutions.

A study of human gut bacteria suggests that high blood pressure with depression may be a completely different disease than high blood pressure without depression.

A Q&A with Brett Carroll, MD, director of Vascular Medicine at Beth Israel Deaconess Medical Center, as he discusses stroke management, DOACs, and warfarin.

A study from the AHA's 2019 Hypertension Scientific Sessions revealed that hypertension was linked to cognitive decline in older patients, but antihypertensive treatment could mitigate this impact.

Particle-depleted diesel exhaust may impair a person's lung function worse than just standard diesel exhaust—while also exposing them to more NO2.

Benzodiazepines are a common yet not very well understood drug class for elderly patients with insomnia.

An analysis of CREDENCE, EMPA-REG, the CANVAS Program, and DECLARE-TIMI 58 found SGLT2 inhibitor use reduced dialysis, transplantation, or death due to kidney disease by 33%.

In a double-blind, phase 2 trial, investigators find that SAGE-17 results in a reduction of depressive symptoms after 2 weeks.

Using a variety of tests to measure cognitive changes, investigators find that gender and education level does not impact cognitive decline as much as health and lifestyle factors.

How do at-risk exacerbation patients present, and what developing therapies could benefit them?

The DocTalk Podcast, a weekly conversation with leaders and experts in medicine, will launch with 3 new episodes on September 9.

Initial PCSK9 inhibitor plus statin therapy helped hospitalized patients achieve LDL-C

In a 53-patient observational study, investigators discover they can safely transplant a HCV-infected kidney into a HCV-negative recipients.

A recent study found that county-level poverty prevalence correlated with both heart failure and coronary heart disease mortality rates.

A pair of phase 3 trials show the single-dose oral drug could have expanded benefits for influenza, just months before an sNDA ruling.

Naeem Khan, MD, and Kiersten Combs, both of Astrazeneca, discuss how recent news from FDA and ESC Congress 2019 could impact dapagliflozin moving forward.

A recent study presented at ESC Congress 2019 found that a 1 unit increase in BMI at 18 years old translated to a hazard ratio of 1.10.

A recent analysis of more than 400,000 from the UK Biobank revealed those who get more or less than 6 to 9 hours of sleep per day increased their risk of heart attack by more than 20%.

A recent study examining how genetic risk factors and lifestyle choices impact premature coronary artery disease found evidence that various factors play a greater role than genetics for younger patients.

Findings from ISAR-REACT 5 show a treatment strategy involving prasugrel significantly reduces patient risk of death, myocardial infarction, or stroke when compared to the other antiplatelet therapy.